Doxylamine Succinate

琥珀酸多西拉敏

Report date: 2025/06/05 20:00:13
NME

Base Information

Drug NameDoxylamine Succinate
Drug Alias Name琥珀酸吡苯甲乙胺Diclegis琥珀酸杜克西拉明Doxylaminum多西拉敏 +[9
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H1 receptor antagonists
TargetsHistamine H1 receptor
Therapy Area/IndicationsHypersensitivitySleep Initiation and Maintenance DisordersRhinitis, Allergic +[4
Global Approved IndicationsHypersensitivity
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1948/04/07
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active IndicationsSleep Initiation and Maintenance Disorders
Inactive IndicationsHypersensitivityRhinitis, AllergicRespiratory Tract Infections

Other Information

ATC CodeR06AA09